Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting
Data highlights clinical proof-of-concept for monitoring metastatic testicular cancer using the Company's proprietary CTC assays, as well as validation of Biocept's high sensitivity circulating tumor DNA tests on Thermo Fisher QuantStudio™5 instrument SAN DIEGO , March 15, 2018 /PRNewswire/ -- 
View HTML
Toggle Summary Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2018
SAN DIEGO , March 12, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable  information to physicians to improve cancer treatment, announces that it will release
View HTML
Toggle Summary Biocept to Present at the 30th Annual ROTH Conference
SAN DIEGO , March 6, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform
Intellectual property estate now includes 25 issued patents for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc.
View HTML
Toggle Summary Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
Published medical guidelines influence treatment practices and can drive clinical adoption of emerging technologies designed to improve the treatment of serious or life-threatening diseases SAN DIEGO , Jan. 30, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
View HTML
Toggle Summary Biocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common Stock
SAN DIEGO , Jan. 26, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces
View HTML
Toggle Summary Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers
Study results to be presented at the Fifth AACR-IASLC International Joint Conference
View HTML
Toggle Summary Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources
Expands intellectual property position to 22 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)
View HTML
Toggle Summary Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota
Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota   SAN DIEGO (December 18, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
View HTML
Toggle Summary Biocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common Stock
SAN DIEGO , Dec. 6, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced that it has
View HTML